T1	intervention 64 73	letrozole
T2	control 77 84	placebo
T3	duration 600 606	5-year
T4	eligibility 671 712	post-menopausal BRCA1/2 mutation carriers
T5	No-of-participants 834 837	113
T6	No-of-participants 922 927	1,505
T7	No-of-participants 1228 1256	Five hundred and thirty-four
